In this article, we discovered an unintentional error that the Combination Index (CI) image of ABC294640 with Obatoclax in HCCC9810 cells in Figure 4B was misplaced during the preparation of figures using GraphPad Prism 6.0 software. The data that was used to calculate the Combination Index using CompuSyn software was correctly presented just above the Combination Index figure (Cell viability curve of HCCC9810 with different inhibitors treatment in Figure 4B).
Figure 4.
ABC294640 acts synergistically with BH3-mimetics in inhibiting cholangiocarcinoma cell growth. A. RBE, HCCC9810 and HuH28 cells were treated with various concentrations of ABC294640 or ABT-263 alone or their combination for 72 h, then the cell viability was analyzed by CCK-8 assay. The results are presented as mean ± SEM from 3-4 independent experiments. The combination index (CI) was determined using the Chou-Talalay Method. CI < 1 indicates that the interaction between ABC294640 and ABT-263 was synergistic. B. RBE, HCCC9810 and HuH28 cells were treated with various concentrations of ABC294640 or Obatoclax alone or their combination for 72 h, then the cell viability was analyzed by CCK-8 assay. The results are presented as mean ± SEM from 3-4 indepen-dent experiments. CI was determined using the Chou-Talalay Method. CI < 1 indicates that the interaction between ABC294640 and Obatoclax was synergistic.
Therefore, we would like to publish this Erratum to reflect this change. These corrections do not change the results or conclusions of this paper. We sincerely apologize for inconvenience caused by unintentional negligence.
The corrected Figure 4 is as follows.